Astellas Pharma's Veoza Recommended by UK's NICE for NHS Use in Treating Menopause-Related Hot Flushes
This NICE recommendation opens up a significant new market for Astellas' Veoza within the UK's public healthcare system.
安斯泰来制药的 Veoza 获得英国 NICE 推荐用于 NHS，扩大了该更年期症状治疗药物的市场准入。
The UK's National Institute for Health and Care Excellence (NICE) has recommended Astellas Pharma's drug, Veoza, for use within the National Health Service (NHS). This recommendation is for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause. The decision makes Veoza an accessible option for women in the UK experiencing these symptoms, following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
This NICE recommendation opens up a significant new market for Astellas' Veoza within the UK's public healthcare system. It provides a non-hormonal treatment option for a large patient population, potentially capturing market share from existing hormonal therapies and establishing Veoza as a key treatment for menopause symptoms in the UK.
此信号在行业全局中的位置。
暂无近期信号追踪。
https://www.thepharmaletter.com/pfizer-news/ice-backs-astellas-veoza-for-nhs-use
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录